论文部分内容阅读
2010年11月19日,美国食品和药品管理局(FDA)发布公告:鉴于丙氧芬(propoxyphene)可导致严重的心脏毒性,停止含有丙氧芬成分的药物在美国市场销售与使用[1]。
On November 19, 2010, the U.S. Food and Drug Administration (FDA) issued a public notice: Due to the serious cardiotoxicity caused by propoxyphene, discontinuation of the propoxyphene-containing drug is marketed and used in the United States [1] .